PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations

Schizophrenia Clinical Trial

Official title: PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations

Status Terminated

Clinical Trial Summary

The primary goal of the present study is to evaluate the utility of mGluR5 binding as measured by PET as biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation.

Clinical Trial Description

The investigators will focus on mGluR5 PET binding as a surrogate measure for level of activity of the mTOR kinase pathway. This study is being conducted by the New York State Psychiatric Institute (NYSPI) and will take place at Columbia University Medical Center (CUMC) in New York City and at a research office in Strasburg, PA. Subjects (n=20) with the CNTNAP2 mutation with schizophrenia or a related condition will be recruited from the Amish and Mennonite communities and brought to CUMC for detailed investigation. Affected individuals will be compared to Amish and Mennonite control subjects drawn from the same families but not harboring CNTNAP2 mutations (n=20). The primary measure will consist of mGluR PET binding in DLPFC. In addition, secondary analyses will assess binding in other brain regions such as hippocampus and visual cortex. Exploratory measures, as well as relationships between PET mGluR5 binding and clinical symptomatology, will be assessed. ;

Related Conditions & MeSH terms

• Schizophrenia

• NCT number: NCT02983058
• Study type: Interventional
• Source: New York State Psychiatric Institute
• Status: Terminated
• Phase: N/A
• Start date: November 2016
• Completion date: July 2017